Research Article | Open Access
Thu T. Duong, James Lim, Vidyullatha Vasireddy, Tyler Papp, Hung Nguyen, Lanfranco Leo, Jieyan Pan, Shangzhen Zhou, H. Isaac Chen, Jean Bennett, Jason A. Mills, "Comparative AAV-eGFP Transgene Expression Using Vector Serotypes 1–9, 7m8, and 8b in Human Pluripotent Stem Cells, RPEs, and Human and Rat Cortical Neurons", Stem Cells International, vol. 2019, Article ID 7281912, 11 pages, 2019. https://doi.org/10.1155/2019/7281912
Comparative AAV-eGFP Transgene Expression Using Vector Serotypes 1–9, 7m8, and 8b in Human Pluripotent Stem Cells, RPEs, and Human and Rat Cortical Neurons
Recombinant adeno-associated virus (rAAV), produced from a nonpathogenic parvovirus, has become an increasing popular vector for gene therapy applications in human clinical trials. However, transduction and transgene expression of rAAVs can differ across in vitro and ex vivo cellular transduction strategies. This study compared 11 rAAV serotypes, carrying one reporter transgene cassette containing a cytomegalovirus immediate-early enhancer (eCMV) and chicken beta actin (CBA) promoter driving the expression of an enhanced green-fluorescent protein (eGFP) gene, which was transduced into four different cell types: human iPSC, iPSC-derived RPE, iPSC-derived cortical, and dissociated embryonic day 18 rat cortical neurons. Each cell type was exposed to three multiplicity of infections (MOI: 1E4, 1E5, and 1E6 vg/cell). After 24, 48, 72, and 96 h posttransduction, GFP-expressing cells were examined and compared across dosage, time, and cell type. Retinal pigmented epithelium showed highest AAV-eGFP expression and iPSC cortical the lowest. At an MOI of 1E6 vg/cell, all serotypes show measurable levels of AAV-eGFP expression; moreover, AAV7m8 and AAV6 perform best across MOI and cell type. We conclude that serotype tropism is not only capsid dependent but also cell type plays a significant role in transgene expression dynamics.
There is an excellent safety record with respect to use of recombinant adeno-associated virus (AAV) vectors in human clinical trials [1–3]. AAV-mediated gene therapy has been shown to rescue retinal and visual function in individuals diagnosed with inherited blinding disorders due to RPE65 mutations [3–5]. rAAVs act by transferring the functional transgene cassette into the targeted cells or tissue where it can then be expressed. The specificity and efficiency of the AAV-mediated gene therapy significantly depend on cell type targeted, the number of vector particles delivered to the cell (and the number of particles that successfully reach the nucleus), immune response, and AAV capsid serotype utilized.
Since animal models are not always available for a given disease (or may have an irrelevant phenotype), recent trend for evaluating proof-of-concept of gene therapy in laboratory studies has focused on use of induced pluripotent stem cell- (iPSC-) based cell models from affected individuals [6–9]. Such models can also be used to study pathologic mechanisms associated with known gene mutations. An advantage of using iPSCs for translational models is that these cells can be differentiated along pathways leading to the three germ layers; endoderm (liver, lung, and pancreas), mesoderm (blood, endothelium, and mesenchymal cells), and ectoderm (brain, skin, and eye). For ophthalmologic evaluation, cells can be differentiated to the retinal cell lineage for the generation of retinal progenitors, retinal pigmented epithelium, retinal ganglion cells, horizontal, amacrine cells, and photoreceptors. These long-term cultures allow for developmental and pathophysiologic modeling. Due to the inaccessibility of the human brain, surrogate in vitro-derived patient cells are valuable for studying neurological disorders, which can affect numerous regions of the brain. The generation of individualized cell types from pluripotent stem cells offers a tremendous tool for developing rAAV therapeutics for ailing individuals; however, comparison of results in in vitro cell-based assays to in vivo or ex vivo models is necessary to ensure the relevance of gene augmentation strategies for ultimate human clinical trials.
The evolution of AAV capsid modifications has made available a new repertoire of vectors with different cell-type tropisms which are valuable for controlling transgene level, onset of expression, viral dosage, and organ- or cell-type specificity. In addition, the transduction efficiency in vivo versus in vitro is hard to predict without direct screening due to complex mechanisms in targeting the cellular receptors on different cell types and species. Although AAV serotype 2 (AAV2) is the most studied with respect to safety and efficacy and is the first AAV vector approved as a drug for the treatment of a retinal disease, other AAV serotypes have great potential and their utility needs to be fully elucidated [1, 2, 10, 11].
Here, our goal is to establish and optimize a methodological approach to identify which of a variety of AAV serotypes is best suited for applications in vitro and ex vivo by defining distributive parameters of AAV-eGFP transgene expression across AAV serotypes 1-9, 7m8, and 8b in numerous cellular models including in iPSC, iPSC-derived RPE, iPSC-derived cortical neurons, and dissociated embryonic day 18 (E18) rat cortical neurons to benefit proof-of-concept AAV translational research. Here, we conclude that AAV7m8 has superior performance for the particular cell types and duration evaluated; however, depending on dosage or time of onset additional serotypes like AAV6 and AAV8 have useful properties.
2.1. Human-Induced Pluripotent Stem Cells Culturing
Two iPSC cell lines (JBWT2 (PBWT2) and JBWT4 (BMC1)) derived from adult individuals without any known disease were evaluated in these studies and have been previously published showing a complete analysis of pluripotent stem characteristics [12, 13]. All human protocols were approved by the institutional review board (IRB) at the University of Pennsylvania, and each donor provided signed informed consent (IRB 808828). iPSC cultures were maintained in iPSC medium (Dulbecco’s modified essential medium/Ham’s F12 nutrient media; DMEM/F12 (50 : 50; Corning)) containing glutamine, penicillin/streptomycin (Invitrogen), 15% KnockOut serum replacement (KSR; Invitrogen), 1 × non-essential amino acids (NEAA; Invitrogen), 0.1 mM β-mercaptoethanol (2-ME; Invitrogen), and 5 ng/mL of basic fibroblast growth factor (bFGF; R&D Systems) on 0.1% gelatin-coated dishes with irradiated mouse embryonic fibroblast (iMEFs). For transduction experiments, cells were maintained on 1 : 100 Matrigel-coated 96-well dishes. Morphological characteristics and flow cytometry of pluripotency markers were evaluated prior to all experiments. Single cells were stained with stage-specific embryonic antigen 3 and 4 (SSEA3: BioLegend 1 : 100, SSEA4: BioLegend) for 30 minutes at room temperature. Following staining and three subsequent washes, cells were resuspended in FACS buffer (1XPBS (Corning) with 0.1% BSA (Sigma-Aldrich) and 0.1% sodium azide (Sigma-Aldrich)). All samples were analyzed on the Accuri C6 (BD Biosciences) software program.
2.2. Retinal Pigmented Epithelium (RPE) Cells
Retinal pigmented epithelium cells were generated from both iPS cell lines and fully characterized as previously published . Cells were maintained in X-VIVO 10 medium (Lonza) plus 1 × pen/strep and 1 × glutamax on tissue culture dishes coated with 1 : 100 growth factor reduced (GFR) Matrigel (Corning). All passaging of RPE were performed using Accutase and replating media contained Thiazovivin (2 μM; Stemgent), which was subsequently removed from X-VIVO media 24 h postsplitting. Monolayer cultures were characterized for RPE morphology and images were taken with Nikon D5600 SLR camera, and RPE were stained for cellular markers. RPE were cultured on 1 : 3 Matrigel-coated dishes, and cells were fixed in 4% paraformaldehyde (PFA; electron microscopy) for 15 minutes at room temperature. Cells were blocked for one hour (5% normal goat serum (CST), 2% BSA (Sigma-Aldrich), and 0.3% Triton X-100 in PBS) and stained with primary antibodies: zonula occludens-1 (Zo-1: Invitrogen 1 : 200) and microphthalmia-associated transcription factor (MITF: Invitrogen 1 : 200) in 5% normal goat serum, 2% BSA, and 0.1% Triton X-100 in PBS overnight. After washing, cells were stained with secondary antibodies (1 : 500, anti-rabbit 488 and anti-mouse 555, Invitrogen) in staining buffer for 2 hours at room temperature. The cells were counterstained with ProLong Gold with DAPI (ThermoFisher). Immunofluorescent images were captured with a Zeiss Axio Imager M2 microscope equipped with epifluorescence and AxioVision 4.6 software. For intracellular staining, cells were fixed using BD perm/fix (BD Biosciences) for 20 minutes at 4°C. Cells were washed and resuspended in saponin buffer (BioLegend). Primary and secondary antibodies for MITF (1 : 50, ThermoFisher) and goat anti-mouse 647 were diluted in saponin buffer, and cells were stained for 30 minutes at room temperature. Isotype controls (mouse, Invitrogen) were used at same protein concentration as primary antibodies and were used as negative controls. Following staining, cells were resuspended in FACS buffer and analyzed on Accuri C6 software program.
2.3. Human-Induced Pluripotent Stem Cell-Derived Cortical Neurons
For the iPSC-cortical neuron differentiations, on day 3, cells were dissociated using TrypLE (Invitrogen) and plated on GFR Matrigel in HES : MEF-conditioned (90 : 10) medium +20 ng/mL of bFGF and supplemented with ROCK inhibitor (10 μM; Y27632, Tocris). Cells were maintained in this media until reaching 100% confluence (day 0). The differentiation was performed as previously published with some modifications [15, 16]. Briefly, on day 0, medium was changed to defined differentiation media (DDM) (DMEM/F12 (50 : 50), 1% N2 (Invitrogen), 2% B27 without vitamin A (Invitrogen), 1 × glutamax, 1 × pen/strep, 1X NEAA supplemented with XAV939 (XAV; 2 μM, Stemgent), SB431542 (SB; 10 μM, Tocris), and LDN (LDN; 100 nM, Stemgent). The medium was replenished daily until day 2. On day 2, cyclopamine (Cyclo; 1 μM, Stemgent) was added to XAV, SB, and LDN. From day 2-10, the medium was replaced daily with DDM plus XAV, SB, LDN, and Cyclo. On days 10-16, DDM plus LDN only was used at daily feeding. Day 16-24, DDM was fed daily. From day 27, 25% of DDM was replaced with Neurobasal media (Invitrogen) every other day until day 33 when 100% Neurobasal was used to maintain long-term cortical cultures. On day 82, cortical cultures were characterized by immunofluorescence using Beta-Tubulin III (Tuj1: Sigma 1 : 1000), special AT-rich sequence-binding protein 2 (Satb2: Abcam 1 : 500) and Coup-TF-interacting protein 2 (CTIP2: Abcam 1 : 1000), and glial fibrillary acidic protein (GFAP: SCBT 1 : 300) as described above. Images were captured using a Nikon Eclipse Ti-2 inverted microscope, NIS Elements Advanced Research software and magnification of 10x.
2.4. Isolation of Rat Cortical Neurons
Rat cortical neuron experiments were performed using isolated cells from embryonic day 18 Sprague-Dawley rat fetuses. All animal experiments were performed in agreement with the National Institutes of Health guidelines and approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC). Rat fetuses were removed from euthanized timed-pregnant dames via caesarean section. Fetuses were then decapitated, and their brains isolated. Cortical neurons were isolated from 4-6 cortical hemispheres, which were dissociated with 0.25% Trypsin/EDTA (Invitrogen) containing DNase I (Roche) at 37°C. Cells were washed three times using HBSS and suspended in neuronal media: Neurobasal media plus 2% B27, 1 × glutamine, and 1 × pen/strep. Analysis of rat cortical neurons were performed to confirm identity using immunofluorescence of Tju1 (Sigma, 1 : 1000), Satb2 (Abcam, 1 : 500), and CTIP2 (Abcam, 1 : 1000) cortical cell markers and GFAP (SCBT: 1 : 300) as described above. Images were captured using a Nikon Eclipse Ti-S inverted microscope, NIS Elements Advanced Research software and magnification of 10x.
2.5. Generation of a Panel of Recombinant Adeno-Associated Virus (AAV) Serotypes Carrying Enhanced GFP cDNA Driven by CMV.CβA Promoter
A panel of 11 recombinant AAV serotypes were generated by the Center for Advanced Retinal and Ocular Therapeutic (CAROT) research vector core. Triple transfection of HEK293T cells with pAAV.CMV.CβA.eGFP and helper plasmids was performed as previously described . The virus was purified by CsCl2 gradient centrifugation, and viral particles were titered by silver staining as vector genome copies/mL . The virus was aliquoted in 0.001% Pluronic F-68 (formulation buffer) in 1 × PBS as single use aliquots and stored at -80°C prior to experimentation.
2.6. AAV Transduction Testing
For transduction experiments, 96-well plates were coated with 1 : 100 GFR Matrigel overnight. Cells were enzymatically detached to create a single-cell suspension prior to plating at a density of approximately 2E4 for iPSC, 8E4 iPSC-RPE, 1E5 iPSC-cortical neuron, and 2E4 rat cortical neuron per well. After 24 to 48 h, cells from a minimum of three wells per dish were disassociated and cell counts were performed. Transduction of rAAV-eGFP serotypes, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV7m8, AAV8, AAV8b, and AAV9, was executed at concentrations of 0, 10,000 (1E4), 100,000 (1E5), and 1,000,000 (1E6) vector genomes per cell (vg/cell) in triplicate. The amount of virus needed to achieve a multiplicity of infection (MOI: 1E4, 1E5, or 1E6 vg/cell) was based on the cell number per well for each AAV serotype. Viral stocks were diluted in 0.001% Pluronic F-68 (formulation buffer) in 1 × PBS when necessary. Representative example of dilution strategy is provided in Supplemental Table 1. For each experiment, a new fresh vial of viral stock was thawed and immediately used for transduction experiments. The day of transduction was considered 0 h. Viral particles were incubated for 24 h at 37°C and 5% CO2 for RPE and cortical cells and 5% CO2 and 5% O2 for iPSC and then replaced with corresponding media for each cell type. The AAV-eGFP expression was measured at four time points (24, 48, 72, and 96 h) postinfection using the Typhoon scanner (GE Healthcare) set for 520, BP40 for the emission filter, and 488 for the excitation filter, PTM 570, focal plane +3 mm. The densities of AAV-eGFP expressing cells were evaluated by ImageJ image processing software (FIJI, protein analyzer). Data represent mean relative fluorescence unit (RFU) in AAV-eGFP fluorescence between three technical replicates per experiment. Data from each group were normalized to the mean of nontransduced control wells. Experiments were performed at least three times. AAV-eGFP expression levels for 1E6 vg/cell was plotted using the scatter plot, 3D bubble plot in excel, to show relative differences in fluorescence between cell types and serotype on a per cell basis.
2.7. Bioinformatics and Statistics
The data of relative fluorescent per cell at three different MOIs were visualized by heat map (i.e., two-dimensional representations in colors). The heat map of each cell type was generated using Seaborn, a visualization library based on Python matplotlib. Fluorescent per cell measurements were parsed from excel datasheets into floating-point vectors with each vector corresponded to all AAV serotypes in each MOI over multiple postinfection measurement times. The colors were based on the relative fluorescent per cell level and ranged from yellow (low) to brown (high) fluorescent intensity. Analysis of variance (ANOVA) (Excel’s Analysis ToolPak) for repeated measures was performed to determine the relationship of cell lines and AAV serotypes on the gene expression effect. To determine the effect of each AAV serotype for each cell line, ANOVA with one factor (i.e., AAV serotype) was used, followed by the post hoc pairwise comparisons (XLSTAT add-ins) with correction for multiple comparisons using Tukey method. For each AAV serotype, the gene expression post-infection across time (48, 72 and 96 h post-infection) was evaluated using repeated measures ANOVA followed by pairwise comparison with correction for multiple comparisons using Tukey method. The differences were considered statistically significant when , <0.01, and <0.001 after correction for multiple comparisons using Tukey method.
3. Results and Discussion
3.1. AAV Tropism in Pluripotent Stem Cells, Derivatives, and Ex Vivo-Isolated Neurons
Pluripotent stem cells can be used to generate numerous cell types which are candidates for rAAV vector studies and disease modeling. Induced pluripotent stem cells mRNA transcripts , many of which are only expressed in the pluripotent state or specific adult cell type. These cells provide a resource for studying gene transfer effects on health and disease. Such studies have been the impetus for initiation of clinical trials for choroideremia [9, 14, 19]. However, AAV tropism in iPSCs and cells derived from them has not been thoroughly explored. Furthermore, the effects of AAV delivery to iPSC-derived cells with ex vivo-isolated cell types have yet to be compared across equivalent cell types. Here, we examined the level of AAV-eGFP expression following the transduction of eleven recombinant AAV (rAAV) vectors on iPSCs, iPSC-derived RPE, iPSC-derived cortical neurons, and ex vivo-isolated rat cortical neurons. The rAAV vectors were generated by packaging a transgene cassette encoding enhanced GFP with a bgh poly(A) sequence driven by the CMV.CßA promoter into the 11 different AAV serotypes. The AAV-eGFP transgene expression was determined at four time points and three MOIs and expressed as relative AAV-eGFP intensity per cell (Figure 1).
3.2. Pattern and Fluorescent Intensity of AAV-eGFP Differed between iPSCs and iPSC-Derived RPEs for rAAV Transductions
Analysis of AAV tropism was performed on iPSCs derived from two individuals, and cell lines were cultured in undifferentiated cell culture conditions to maintain a pluripotent state. Prior to transduction, to ensure cultures were a uniform population of pluripotent stem cells (PSC), cultures were monitored for PSC morphological characteristics (phase) and pluripotent surface markers expression of SSEA3 and SSEA4, by flow cytometry (Figure 2(a)). Aliquots of iPSC cultures were transduced with one of 11 different serotypes and MOIs of 1E4, 1E5, and 1E6 vg/cell. The AAV-eGFP expression postinfection was recorded using live cell imaging using a Typhoon fluorescent plate reader at 24, 48, 72, and 96 h. The expression of GFP was observed to be dose and time dependent, and only at the highest dose (MOI of 1E6) were all 11 rAAV expressed to measurable levels (Figures 2(b) and 2(c); ; Figure 2(e)). AAV-eGFP expression was first noticeable at approximately 48 h postinfection, and the level of expression was maintained throughout the 96 h of experimentation. It is important to note that the iPSCs after 96 h are 100% confluent resulting in spontaneous differentiation; therefore, the evaluation at later time points of the pluripotent state is no longer possible. There were significant differences across rAAV vectors used, and the expression of AAV-eGFP from highest to lowest was as follows at MOI: 1E6 vg/cells: AAV3, AAV7m8, AAV6, AAV2, AAV8, AAV1, AAV9, AAV8b, AAV4, AAV7, and AAV5 (Figure 2; Supplemental Table 2). AAV7m8 was the only serotype to yield expression across all vector dosages (1E4, 1E5, and 1E6 vg/cell). AAV3 and AAV6 were the only other rAAVs to yield expression at more than one dosage (1E5 and 1E6 vg/cell). Identifying the appropriate AAV vector for gene delivery in pluripotent stem cells (PSCs) is important, and expanding our repertoire of tools is essential for studies probing the biology in health and disease. Previous work has investigated the use of AAV1, AAV2, AAV6, and AAV9 for transduction of iPSC and demonstrated that AAV2 and AAV6 have high tropism for pluripotent stem cells . Our work supports these findings and shows that AAV3 and AAV7m8 yield substantially increased GFP expression. Moreover, the characteristics of AAV transduction with respect to pluripotent stem cells differentiated to ocular and brain cell types will be pivotal for a number of translational studies as these areas are prime targets for gene augmentation strategies prerequisite to gene therapy human clinical trials.
RPE cells have been subject to a number of clinical interventions for the treatment of vision disorders such as retinitis pigmentosa (RP), Leber’s congenital amarosis (LCA), advanced neovascular age-related macular degeneration, and choroidal neovascularization [10, 21–23]. The differentiation of iPSCs to retinal pigmented epithelium (RPE) cells provides for structurally and functionally valuable tools for genetic and translational studies [19, 24–26]. The predominant rAAVs for vector delivery to RPE have been AAV2 and AAV5, which are shown to transduce RPE with high efficiency . However, AAV7m8 has proved to be an excellent candidate for both in vitro and in vivo studies based on its tropism for iPSC-RPE and nonhuman primate (NHP) retina using subretinal injections [14, 27]. Here, we expand the list of rAAV serotypes available for in vitro transduction of human iPSC-RPEs. Analysis of iPSC-RPEs prior to transduction experiments demonstrated the characteristic “cobblestone” appearance under phase contrast microscopy and colabeling with MITF and Zo-1 using immunohistochemistry showed distinct nuclear and cytoplasmic staining of RPE markers in >95% of cultured cells, respectively, and confirmed by intracellular flow cytometry analysis of MITF (Figure 2(d), Supplementary Figure 1(a)). Similar to iPSCs, there were time, dosage, and vector effects observed in iPSC-RPEs after administration of 1E6 vg/cell (). We identified 1E6 to be the only dosage with detectable AAV-eGFP expression among all rAAV serotypes (Figure 2(e)). AAV-eGFP fluorescence did not appear until 48 h, similar to iPSCs; however, there was a time-dependent expression effect with maximal fluorescence intensity per cell being reached at 96 h postinfection. This time, delay may relate to the time needed to convert the single stranded DNA in AAV to a double-stranded transcriptionally competent form [28, 29]. Similar time delays have been noted after subretinal delivery in vivo .
RPE cells were able to be maintained on culture dishes for months postinfection and eGFP expression was also maintained; moreover, the level of transgene expression remained consistent with expression measured at 96 h posttransduction for weeks (Supplementary Figure 2). In the majority of the rAAV serotypes administered, there was noticeable AAV-eGFP expression at the lowest MOI (1E4 vg/cell), but expression was increased by more than ~3-fold (1E5 vg/cell) and ~7-fold (1E6 vg/cell) at the higher MOIs across most rAAVs (Figure 2(f)). The increases in intensity or AAV-eGFP expression were not directly associated with the vector copy number increase (10 and 100x, respectively), which could reflect a threshold for AAV binding to receptors, endocytosis mechanisms, and postentry processing of the capsids presented to RPE cells. A pattern of AAV-eGFP expression was observed in RPEs from highest to lowest were as follows at MOI: 1E6 vg/cells: AAV6, AAV7m8, AAV4, AAV3, AAV5, AAV1, AAV2, AAV8, AAV8B, AAV7, and AAV9 (Figure 2, Supplemental Table 2). The greatest fluorescent intensity of AAV6-eGFP was unexpected as this vector likely arose from recombination between AAV1 and AAV2 . However, it has been used successfully in a previous study to deliver a transgene in vivo to RPE cells . As previously reported, in vivo comparative studies in murine, rat, canine, and NHP models have shown AAV7m8, AAV2, and AAV4 to have superior transduction after subretinal AAV administration [27, 32–34]. Our studies demonstrate a correlation of in vitro findings in iPSC-RPEs with in vivo transduction of RPEs and thus show the utility of iPSC-RPEs as a surrogate for gene delivery effects in vivo.
3.3. AAV Tropism in Cortical Neurons Derived from iPSC and Ex Vivo Rat Cortical Neurons
Cortical neurons were generated from the same iPS cells as described above, and the phenotype of these neurons (day 82+) was determined by immunocytochemical staining with markers of supragranular (layers II/III; Satb2) and infragranular (layer V; CTIP2) neurons prior to AAV transduction experiments. Within these cultures, two different cell types were predominant, either postmitotic pyramidal neurons (Tuj1+, ) or astrocytes (GFAP+, ) as identified by immunocytochemical analysis (Figure 3(a), Supplementary Figure 2(b)). For a comparison of iPSC-derived cortical neurons to ex vivo-isolated neurons, we isolated cortical neurons from rats at embryonic day 18 and stained with Satb2/CTIP2/TUJ1/GFAP (Figure 3(d), Supplementary Figure 2(c)). Similar to differentiated human cortical neurons, the majority of rat cortical cultures were predominantly cortical neurons expressing Tuj1 () and astrocytes expressing GFAP ().
The fluorescence intensity of eGFP for all rAAV serotypes was significantly lower (~2-4-fold, ) for iPSC-cortical neurons compared to rat cortical cells. The best performing rAAV in iPSC neurons across time and dosage was AAV7m8 (Figure 3(b)). The highest AAV-eGFP expression was observed with AAV8B-eGFP, which was only significantly expressed at the highest MOI (1E6 vg/cell) and onset of expression was later at 96 h. We observed iPSC-cortical neuron AAV-eGFP expression from highest to lowest as follows at MOI: 1E6 vg/cells: AAV8b, AAV7m8, AAV8, AAV6, AAV3, AAV1, AAV9, AAV7, AAV2, AAV4, and AAV5 (Figure 3, Supplemental Table 2). This expression was time dependent with expression increasing across all times observed with maximal expression measured at 96 h (). The AAV-eGFP expression was quite different between iPSC neurons and rat cortical neurons (Figure 4). The AAV-eGFP expression in rat cortical neurons from highest to lowest was as follows at MOI: 1E6 vg/cells: AAV6, AAV7m8, AAV7, AAV1, AAV8b, AAV4, AAV8, AAV9, AAV5, AAV3, and AAV2 (Figure 3, Supplemental Table 2). Previous work shows stable transgene expression when ex vivo hippocampal and cortical cultures were transduced with a panel of AAV serotype . Similar to our studies, AAV6 and AAV1 are shown to be neurotrophic serotypes with high transduction efficiencies and transgene expression. The AAV7m8 serotype was found to have the highest AAV-eGFP expression across cortical neurons investigated.
3.4. rAAV Tropism Varies across Cell Types Resulting in Substantial Expression Differences
Although initial AAV tropism studies focused on AAV2, other serotypes have recently been shown to perform better in vitro and in vivo postadministration [11, 27, 36, 37]. We show that rAAV packaged using 11 different serotypes and one transgene cassette have substantial differences between cell type with respect to level of eGFP expression and time of onset. In particular, AAV7m8 is the leading candidate for transduction across all cell types and MOIs examined in these studies. The expression difference using AAV7m8 can range from 4 to 17-fold within the same vector genome copy number using the same transgene vector. AAV6 had significant expression across all cell types thereby highlighting its potential for advancing mechanistic and translational studies; additionally, AAV8 serotypes have efficacy in neuronal subtypes. To compare the level of AAV-eGFP expression across cell types, we evaluated AAV-eGPF expression on a per cell basis. The cell type most strongly transduced was the retinal pigmented epithelium cell compared to the other cell types (Figure 4). Ex vivo rat cortical neurons were observed to have high level of GFP expression compared to in vitro iPSC-derived cortical neurons. However, due to species differences, it is difficult to determine if AAV-eGFP expression levels in neurons are due to promoter activity or as result of serotype difference. iPSCs were shown to have low to intermediate level of GFP expression, which was serotype dependent. The performance of individual AAV serotypes differs significantly presumably due to capsid proteins; however, the individual cell tropism has been suggested to be receptor mediated and endocytosis or intracellular pathway related [38–40]. This data indicates that cell type-specific difference rather than AAV capsid affects the AAV tropism.
Important to note, having the highest level of AAV-eGFP expression will not always provide optimal results as the biology associated with transgene element needs to be considered. The endogenous level and transgene function, transcription factor, structural protein, chaperone, and enzymes, all need to be evaluated during gene augmentation testing. Evaluation of gene expression kinetic profiles also provides insight in the appropriate timing for the evaluation of maximal and sustained AAV-transgene expression which can be used for preclinical and clinical viral preparation validation. Therefore, having a group of rAAVs with variable gene expression kinetic, protein expression profiles, and cell tropisms is essential for selecting the appropriate levels of transgene expression for a given application.
The data used to support the findings of this study are available from the corresponding author upon request.
J.B. holds intellectual property related to the engineered AAV serotype, AAV8b.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
TTD, TP, VV, JB, and JAM are responsible for the strategy, conception, and writing of the manuscript. JAM, P.H., and TTD are responsible for the iPSC maintenance and RPE differentiations. TTD, LL, and JAM are responsible for the RPE characterization. JL and HIC are responsible for the iPSC cortical generations. SZ and JP are responsible for the rAAV production. JL and HIC are responsible for the isolation of embryonic rat cortical neurons. TP and HN are responsible for the computational analysis, TTD, TP, VV, JB, and JAM are responsible for the data analysis, interpretation, and contribution to experimental design. All coauthors reviewed and edited the manuscript.
This study was supported in part by the Vietnam Education Foundation (VEF) fellowship (http://www.vef.gov), the Center for Advanced Retinal and Ocular Therapeutics (CAROT), the Foundation for Fighting Blindness (FFB), the Department of Veterans Affairs (IK2RX002013, HIC), the Robert and Susan Heidenberg Investigative Research Fund for Ocular Gene Therapy, the Research to Prevent Blindness, the F. M. Kirby Foundation, the National Institute of Health vision core grant P30EY01583-26, and the Paul MacKall and Evanina Bell MacKall Trust.
Supplemental Table 1: representative AAV dosage, titer, and MOI calculation for iPSC, RPE, and human and rat cortical cells. Supplemental Table 2: relative fluorescence intensity (R.F.U.) per cell at 96 h at MOI (1E6 vg/cell) Supplementary Figure 1: stable GFP transgene expression in RPE. (a) The AAVeGFP expression in RPE at d4 (96 h) and d18 for a dosage of 1E6 vg/cell shows similar expression in longer term cultures. There is no statistically significant difference between day 4 and day 18 in any of the AAV. Supplementary Figure 2: RPE and cortical neuron characterization. (a) Flow cytometric analysis of intracellular MITF protein expression. Greater than 95% of RPE expresses MITF. Plot showing MITF positive cells (blue) relative to mouse isotype control antibody (red). (b, c) Immunophenotyping of human and rat cortical neurons and astrocytes showing neuron-specific class III beta-tubulin (TUJ1; green) and glial fibrillary acidic protein (GFAP; red), respectively. Images were captured at 20x magnification (human iPSC cortical) and 10x magnification (rat cortical). (Supplementary Materials)
- J. Bennett, J. Wellman, K. A. Marshall et al., “Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial,” The Lancet, vol. 388, no. 10045, pp. 661–672, 2016.
- X. Wan, H. Pei, M.-J. Zhao et al., “Efficacy and safety of rAAV2-ND4 treatment for Leber's hereditary optic neuropathy,” Scientific Reports, vol. 6, no. 1, article 21587, 2016.
- S. Russell, J. Bennett, J. A. Wellman et al., “Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial,” The Lancet, vol. 390, no. 10097, pp. 849–860, 2017.
- A. M. Maguire, K. A. High, A. Auricchio et al., “Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial,” The Lancet, vol. 374, no. 9701, pp. 1597–1605, 2009.
- A. M. Maguire, F. Simonelli, E. A. Pierce et al., “Safety and efficacy of gene transfer for Leber's congenital amaurosis,” The New England Journal of Medicine, vol. 358, no. 21, pp. 2240–2248, 2008.
- M. Nizzardo, C. Simone, F. Rizzo et al., “Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model,” Science Advances, vol. 1, no. 2, article e1500078, 2015.
- Y. Li, W.-H. Wu, C.-W. Hsu et al., “Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects,” Molecular Therapy, vol. 22, no. 9, pp. 1688–1697, 2014.
- S. Torriano, N. Erkilic, V. Faugère et al., “Pathogenicity of a novel missense variant associated with choroideremia and its impact on gene replacement therapy,” Human Molecular Genetics, vol. 26, no. 18, pp. 3573–3584, 2017.
- V. Vasireddy, J. A. Mills, R. Gaddameedi et al., “AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models,” PLoS One, vol. 8, no. 5, pp. e61396–e61313, 2013.
- J. S. Heier, S. Kherani, S. Desai et al., “Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial,” The Lancet, vol. 390, no. 10089, pp. 50–61, 2017.
- M. S. Rafii, T. L. Baumann, R. A. E. Bakay et al., “A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease,” Alzheimer's & Dementia, vol. 10, no. 5, pp. 571–581, 2014.
- J. A. Mills, K. Wang, P. Paluru et al., “Clonal genetic and hematopoietic heterogeneity among human-induced pluripotent stem cell lines,” Blood, vol. 122, no. 12, pp. 2047–2051, 2013.
- S. K. Sullivan, J. A. Mills, S. B. Koukouritaki et al., “High-level transgene expression in induced pluripotent stem cell–derived megakaryocytes: correction of Glanzmann thrombasthenia,” Blood, vol. 123, no. 5, pp. 753–757, 2014.
- T. T. Duong, V. Vasireddy, P. Ramachandran et al., “Use of induced pluripotent stem cell models to probe the pathogenesis of choroideremia and to develop a potential treatment,” Stem Cell Research, vol. 27, pp. 140–150, 2018.
- A. M. Maroof, S. Keros, J. A. Tyson et al., “Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells,” Cell Stem Cell, vol. 12, no. 5, pp. 559–572, 2013.
- I. Espuny-Camacho, K. A. Michelsen, D. Gall et al., “Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo,” Neuron, vol. 77, no. 3, pp. 440–456, 2013.
- J. Y. Song, P. Aravand, S. Nikonov et al., “Amelioration of neurosensory structure and function in animal and cellular models of a congenital blindness,” Molecular Therapy, vol. 26, no. 6, pp. 1581–1593, 2018.
- J. A. Mills, P. S. Herrera, M. Kaur et al., “NIPBL+/− haploinsufficiency reveals a constellation of transcriptome disruptions in the pluripotent and cardiac states,” Scientific Reports, vol. 8, no. 1, p. 1056, 2018.
- N. Cereso, M. O. Pequignot, L. Robert et al., “Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient,” Molecular Therapy - Methods & Clinical Development, vol. 1, article 14011, 2014.
- K. Rapti, F. Stillitano, I. Karakikes et al., “Effectiveness of gene delivery systems for pluripotent and differentiated cells,” Molecular Therapy - Methods & Clinical Development, vol. 2, article 14067, 2015.
- R. E. MacLaren, M. Groppe, A. R. Barnard et al., “Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial,” The Lancet, vol. 383, no. 9923, pp. 1129–1137, 2014.
- G. Schnabolk, N. Parsons, E. Obert et al., “Delivery of CR2-fH using AAV vector therapy as treatment strategy in the mouse model of choroidal neovascularization,” Molecular Therapy - Methods & Clinical Development, vol. 9, pp. 1–11, 2018.
- N. G. Ghazi, E. B. Abboud, S. R. Nowilaty et al., “Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial,” Human Genetics, vol. 135, no. 3, pp. 327–343, 2016.
- T. A. Blenkinsop, J. S. Saini, A. Maminishkis et al., “Human adult retinal pigment epithelial stem cell–derived RPE monolayers exhibit key physiological characteristics of native tissue,” Investigative Ophthalmology & Visual Science, vol. 56, no. 12, pp. 7085–7099, 2015.
- J. S. Saini, B. Corneo, J. D. Miller et al., “Nicotinamide ameliorates disease phenotypes in a human iPSC model of age-related macular degeneration,” Cell Stem Cell, vol. 20, no. 5, pp. 635–647.e7, 2017.
- A. Vugler, A.-J. Carr, J. Lawrence et al., “Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, expansion and retinal transplantation,” Experimental Neurology, vol. 214, no. 2, pp. 347–361, 2008.
- C. Hinderer, P. Bell, N. Katz et al., “Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals,” Human Gene Therapy, vol. 29, no. 1, pp. 15–24, 2018.
- F. K. Ferrari, T. Samulski, T. Shenk, and R. J. Samulski, “Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors,” Journal of Virology, vol. 70, no. 5, pp. 3227–3234, 1996.
- K. J. Fisher, G. P. Gao, M. D. Weitzman, R. DeMatteo, J. F. Burda, and J. M. Wilson, “Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis,” Journal of Virology, vol. 70, no. 1, pp. 520–532, 1996.
- G. M. Sarra, C. Stephens, F. C. Schlichtenbrede et al., “Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus,” Vision Research, vol. 42, no. 4, pp. 541–549, 2002.
- W. Xiao, N. Chirmule, S. C. Berta, B. McCullough, G. Gao, and J. M. Wilson, “Gene therapy vectors based on adeno-associated virus type 1,” Journal of Virology, vol. 73, no. 5, pp. 3994–4003, 1999.
- J.-J. Pang, A. Lauramore, W.-T. Deng et al., “Comparative analysis of in vivo and in vitro AAV vector transduction in the neonatal mouse retina: effects of serotype and site of administration,” Vision Research, vol. 48, no. 3, pp. 377–385, 2008.
- M. Weber, J. Rabinowitz, N. Provost et al., “Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery,” Molecular Therapy, vol. 7, no. 6, pp. 774–781, 2003.
- K. E. Guziewicz, B. Zangerl, A. M. Komáromy et al., “Recombinant AAV-mediated BEST1 transfer to the retinal pigment epithelium: analysis of serotype-dependent retinal effects,” PLoS One, vol. 8, no. 10, article e75666, 2013.
- N. C. Royo, L. H. Vandenberghe, J.-Y. Ma et al., “Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity,” Brain Research, vol. 1190, pp. 15–22, 2008.
- D. G. Hickey, T. L. Edwards, A. R. Barnard et al., “Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina,” Gene Therapy, vol. 24, no. 12, pp. 787–800, 2017.
- T. M. Buck, L. P. Pellissier, R. M. Vos, E. H. C. van Dijk, C. J. F. Boon, and J. Wijnholds, “AAV serotype testing on cultured human donor retinal explants,” in Retinal Gene Therapy, vol. 1715 of Methods in Molecular Biology, pp. 275–288, Humana Press, New York, NY, USA, 2018.
- J. Hansen, K. Qing, H. J. Kwon, C. Mah, and A. Srivastava, “Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts,” Journal of Virology, vol. 74, no. 2, pp. 992–996, 2000.
- D. Duan, Z. Yan, Y. Yue, W. Ding, and J. F. Engelhardt, “Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation,” Journal of Virology, vol. 75, no. 16, pp. 7662–7671, 2001.
- B. Hauck and W. Xiao, “Characterization of tissue tropism determinants of adeno-associated virus type 1,” Journal of Virology, vol. 77, no. 4, pp. 2768–2774, 2003.
Copyright © 2019 Thu T. Duong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.